68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging: Preclinical investigation and dosimetry;68Ga-NODAGA-RGDyK zur αvβ3-integrin-PET-bildgebung - präklinische untersuchungen und dosimetrie

NuklearMedizin

Volumn 50, Issue 6, 2011, Pages 225-233

  Buchegger, F ^a,b   Viertl, D ^a   Baechler, S ^a   Dunet, V ^a   Kosinski, M ^a   Poitry Yamate, C ^c   Ruegg C ^d   Prior, J O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c EPFL   (Switzerland)

^d UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

v 3; 68Ga NODAGA RGDyK; Cyclic RGDyK; Integrin; PET imaging; RGD peptide

Indexed keywords

CYCLO[ARGINYLGLYCYL ALPHA ASPARTYL DEXTRO TYROSYL N6 [[4,7 BIS(CARBOXYMETHYL)OCTAHYDRO 1H 1,4,7 TRIAZONIN 1 YL]ACETYL]]LYSINE GALLIUM GA 68; GALLIUM 68; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; DIAGNOSTIC AGENT; GALLIUM; HETEROCYCLIC COMPOUND; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; ANTIBODY SPECIFICITY; BODY BURDEN; CHEMISTRY; DRUG SCREENING; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SYNTHESIS; TUMOR CELL LINE; WHOLE BODY COUNTING;

ANIMALS; BODY BURDEN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; INTEGRIN ALPHAVBETA3; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; WHOLE-BODY COUNTING;

EID: 82755171265     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0416-11-06     Document Type: Article

References (25)

1. Beer AJ, Haubner R, Goebel M et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46: 1333-1341.
2. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. J Nucl Med 2006; 47: 763-769.
3. Benard J, Da Silva J, De Blois MC et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985; 45: 4970-4979.
4. 64Cu-labeled RGD peptide. Bioconjugate Chem 2004; 15: 41-49.
5. Cruet-Hennequart S, Maubant S, Luis J et al. Alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 2003; 22: 1688-1702.
6. 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008; 35: 1507-1515.
7. 68Ga-labeled RGD conjugates show improved PET imaging of {alpha}{nv}{beta}3 integrin expression and facile radiosynthesis. J Nucl Med 2011; 52: 1276-1284.
8. 68Ga-somatostatin antagonists: The chelate makes the difference. J Nucl Med 2011; 52: 1110-1118.
9. Freudenberg R, Oehme L, Menkel S et al. Strahlenbelastung der Blasenwand nach nuklearmedizinischer Radiopharmakaapplikation-Anwendung des MIRD Pamphlet 14. Nucl Med 2011; 50: A112.
10. Heckmann D, Kessler H. Design and chemical synthesis of integrin ligands. Methods Enzymol 2007; 426: 463-503.
11. 68Galabeled c(RGDyK)-isothiocyanato benzyl-1,4,7-triaza cyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008; 49: 830-836.
12. 68Ga]NODAGA-RGD for imaging alpha(v)beta(3) integrin expression. Eur J Nucl Med Mol Imaging 2011; 38: 1303-1312.
13. 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007; 48: 1162-1171.
14. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta(3) expression. Eur J Nucl Med Mol Imaging 2008; 35: 1100-1108.
15. 18F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging 2009; 36: 1296-1307.
16. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Ann Review Immunol 2007; 25: 619-647.
17. Otis M, Campbell S, Payet MD et al. In adrenal glomerulosa cells, angiotensin II inhibits proliferation by interfering with fibronectin-integrin signaling. Endocrinology 2008; 149: 3435-3445.
18. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 35: 72-79.
19. Pidgeon GP, Tang K, Cai YL et al. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res 2003; 63: 4258-4267.
20. 68Ga]NODAGARGD. J Nucl Med 2011; 52: 120P.
21. Reardon DA, Neyns B, Weller M et al. Cilengitide: an RGD pentapeptide alphavbeta3 and alphavbeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol 2011; 7: 339-354.
22. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46: 1023-1027.
23. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
24. Stewart PL, Nemerow GR. Cell integrins: commonly used receptors for diverse viral pathogens. Trends Microbiol 2007; 15: 500-507.
25. Wang W, Luo BH. Structural basis of integrin transmembrane activation. J Cell Biochem 2010; 109: 447-452.